COUCH Health Publishes ‘Inclusive Terminology Report’ to Support Diversity in Clinical Trials
COUCH Health announced the publication of a new report “Exploring the Impact of Terminology on Inclusivity in Healthcare” as part of the Demand Diversity campaign.
The report was conducted and produced by the COUCH Health in-house research team, who consulted with 300 people from across a range of different groups to understand how they perceived terminology which is commonly found across healthcare and medical literature.
The initial phase of qualitative research was supplemented by quantitative research in the shape of a survey, which was co-designed with 20 people from across the UK and the US. The resulting research explores terminology across the following areas: disability, race and ethnicity, sexuality, and gender.
Access the full report here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
